New injection for autoimmune diseases takes first step in human testing
NCT ID NCT07366866
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a new medicine called GenSci136 in 48 healthy adults in China. The goal is to check if a single shot is safe and how the body processes it. This is a first step toward possibly treating autoimmune diseases, where the immune system attacks the body.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Huashan Hospital
RECRUITINGShanghai, Shanghai Municipality, 200040, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Genetic hunt for hidden causes of mysterious inflammatory diseases
- Biopsy tolerance study ends early – what we know
- Could a single injection reprogram immune cells to tame lupus and scleroderma?
- Your genes, your meds: 1200-Patient study tests smarter prescribing
- Could a stem cell transplant stop the immune system from attacking the brain?
- When to boost? new trial seeks best COVID-19 shot timing for vulnerable patients